OKYO Pharma will participate in the Cantor Global Healthcare Conference on September 9-11, 2026, including a fireside chat and one-on-one meetings. The investor-facing appearance follows positive FDA Type D meeting feedback on urcosimod’s regulatory and clinical path and a strengthened cash position in its annual report.

Key Highlights

  • Flavio Mantelli and Gary Jacob will represent OKYO Pharma at the conference.
  • OKYO Pharma linked its participation to positive feedback from a U.S. FDA Type D meeting.
  • OKYO Pharma will participate in the Cantor Global Healthcare Conference.
  • A fireside chat is scheduled for September 10, 2026.

OKYO Pharma Ltd (NASDAQ: OKYO) will participate in the Cantor Global Healthcare Conference, with a fireside chat scheduled for September 10, 2026. The clinical-stage biopharmaceutical company is developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.

Cantor Conference Features OKYO Executives

The conference is being held September 9-11, 2026. Chief Medical Officer Flavio Mantelli, MD, PhD, and Chief Development Officer Gary Jacob, PhD, will represent OKYO Pharma in the discussion. Eric Fitzgerald of Cantor Fitzgerald will moderate the session. The company’s ordinary shares are listed on the Nasdaq Capital Market.

FDA Feedback Supports Urcosimod Path

OKYO Pharma said its conference presence follows positive feedback from a U.S. Food and Drug Administration Type D meeting. The feedback validated the regulatory and clinical path forward for urcosimod. The company also pointed to its annual report, which reflected a strengthened cash position. OKYO Pharma describes its development work as focused on neuropathic corneal pain and anterior segment eye diseases. Its activities include investigational therapies in those areas.